Shares of Presbia PLC (NASDAQ:LENS) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus price target of $11.00 for the company and are forecasting that the company will post ($0.26) EPS for the current quarter, according to Zacks. Zacks has also assigned Presbia an industry rank of 172 out of 265 based on the ratings given to its competitors.
A number of research firms recently issued reports on LENS. ValuEngine upgraded shares of Presbia from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Jefferies Group LLC restated a “buy” rating and set a $10.00 price objective (down previously from $11.00) on shares of Presbia in a report on Friday, October 6th. Finally, Zacks Investment Research downgraded shares of Presbia from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th.
Presbia (LENS) traded up $0.03 during midday trading on Friday, reaching $3.37. 211 shares of the company were exchanged, compared to its average volume of 4,358. Presbia has a 1-year low of $1.86 and a 1-year high of $5.88. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.02 and a quick ratio of 2.94.
An institutional investor recently raised its position in Presbia stock. FMR LLC grew its holdings in shares of Presbia PLC (NASDAQ:LENS) by 0.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,568,278 shares of the medical instruments supplier’s stock after purchasing an additional 13,375 shares during the quarter. FMR LLC owned about 15.15% of Presbia worth $5,856,000 at the end of the most recent reporting period. 16.50% of the stock is owned by institutional investors and hedge funds.
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with MarketBeat.com's FREE daily email newsletter.